Skip to main content
FEMY logo

Femasys Inc. (FEMY) Stock Price & Analysis

Femasys Inc. (FEMY) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $1.15 (+2.68%), as of the Nov 18, 2026 trading session; market cap $9.95M.

Educational signal · not a buy or sell recommendation · How to read this

$1.15 +$0.03 (+2.68%) Market Cap $9.95M

Femasys Inc. · FEMY · NASDAQ

Femasys Inc. is a biomedical company focused on developing and commercializing innovative solutions for the women's healthcare market. Their portfolio includes permanent birth control, artificial insemination, and diagnostic products.

Price as of Nov 18, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Femasys (FEMY)

Weak
Business Quality Poor (15)
Financial Safety Okay (47)
Valuation Fair (68)
Growth Durability Shrinking (18)
Momentum Falling (18)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and stalling growth, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $729,394 (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z -5.50 · Piotroski F 1

Holding back: weak fundamentals, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for FEMY (57 recorded, newest six shown)
RecordedScoreBand
18Weak
18Weak
20Weak
20Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.15
Change on the day+2.68%
52-week range$1.15 – $20.80
Market capitalisation$9.95M—
Shares traded on the day132.5K

Price & events

Other perspectives

Council score for Femasys (FEMY): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Moderate
Growth Durability Negative
Momentum Negative

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Femasys (FEMY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Femasys Inc. (FEMY) is listed on NASDAQ. It employs 53 people and is led by Kathy Lee-Sepsick. In Q3 FY2025 it reported revenue of $729,394 and net income of -$4M. The market values it at $9.95M.

2 · Latest results

What do the latest results show for Femasys (FEMY)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $729,394. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$729,394-$4M-$2.05 (diluted)
Q4 FY2025$813,387-$4M—
Q1 FY2026$424,889$846,100$0.22 (diluted)
Q2 FY2026$331,827-$4M-$1.33 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Femasys (FEMY)?

Short answer

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -5.50 · Piotroski F 1. Trailing ratios: ROA -84.2% · current ratio 2.14.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -5.50 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Femasys compare with its peers?

Short answer

Femasys's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Pro-Dex, Inc. (PDEX) Same industry, near in market value$63.94 Nov 18, 2026$205M87 5-pillar Nov 18, 2026
Regentis Biomaterials Ltd. (RGNT) Same industry, near in market value$1.14 Nov 18, 2026$8.01M64 5-pillar Nov 18, 2026
Anbio Biotechnology (NNNN) Same industry, near in market value$3.60 Nov 18, 2026$158M55 5-pillar Nov 18, 2026
Daxor Corporation (DXR) Same industry, near in market value$7.94 Nov 18, 2026$46.4M47 5-pillar Nov 18, 2026
Precision Optics Corporation, Inc. (POCI) Same industry, near in market value$4.18 Nov 18, 2026$46.0M39 5-pillar Nov 18, 2026
Retractable Technologies, Inc. (RVP) Same industry, near in market value$0.62 Nov 18, 2026$18.6M37 5-pillar Nov 18, 2026
Nephros, Inc. (NEPH) Same industry, near in market value$2.89 Nov 18, 2026$31.4M31 5-pillar Nov 18, 2026
WORK Medical Technology Group Ltd. (WOK) Same industry, near in market value$1.16 Nov 18, 2026$5.18M30 5-pillar Nov 18, 2026
Microbot Medical Inc. (MBOT) Same industry, near in market value$0.72 Nov 18, 2026$48.5M30 5-pillar Nov 18, 2026
Harvard Bioscience, Inc. (HBIO) Same industry, near in market value$9.00 Nov 18, 2026$41.2M26 5-pillar Nov 18, 2026
Milestone Scientific Inc. (MLSS) Same industry, near in market value$0.26 Nov 18, 2026$23.3M23 5-pillar Nov 18, 2026
KORU Medical Systems, Inc. (KRMD) Same industry, near in market value$3.45 Nov 18, 2026$150M23 5-pillar Nov 18, 2026
Femasys (FEMY) — this page$1.15$9.95M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 30, 2026

Transactions
21
Identified insiders
10
Purchases
5
Sales
0
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held FEMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported FEMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Femasys (FEMY)?

Read these with our analysis →

Femasys Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the FEMY research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for FEMY?

FEMY carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Femasys Inc. is a biomedical company focused on developing and commercializing innovative solutions for the women's healthcare market.

Is FEMY a good stock to buy?

Stock Expert AI does not rate FEMY buy, sell or hold. Femasys Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the FEMY stock price today?

The last price recorded for Femasys Inc. (FEMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Femasys Inc. do?

The company's product portfolio includes FemBloc, a permanent birth control solution; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.

What are the key factors to evaluate for FEMY?

Femasys Inc. (FEMY) holds a MoonshotScore in the low range. Focus on women's healthcare addresses a large and growing market with unmet needs. Not financial advice.

How frequently does FEMY data refresh on this page?

FEMY's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven FEMY's recent stock price performance?

Femasys Inc. (FEMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio addressing unmet needs in women's healthcare. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider FEMY overvalued or undervalued right now?

Femasys Inc. (FEMY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of FEMY?

Fractional-share availability for Femasys Inc. (FEMY) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 9 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.